Glenmark’s IGI Strikes $1.9 Billion Global Licensing Deal with AbbVie for Cancer Drug ISB 2001

Unknown Apr 02, 2026 950 Views

Glenmark Pharmaceuticals’ biotech arm, Ichnos Glenmark Innovation (IGI), has signed an exclusive global licensing agreement with AbbVie for its lead investigational asset, ISB 2001—a first-in-class trispecific antibody targeting multiple myeloma. Key Highlights...